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Abstract We have recently reported that HIV-1 protease (PR)
cleaves the initiation factor of translation eIF4GI [Ventoso et
al., Proc. Natl. Acad. Sci. USA 98 (2001) 12966^12971]. Here,
we analyze the proteolytic activity of HIV-1 PR on eIF4GI and
eIF4GII and its implications for the translation of mRNAs.
HIV-1 PR e⁄ciently cleaves eIF4GI, but not eIF4GII, in cell-
free systems as well as in transfected mammalian cells. This
speci¢c proteolytic activity of the retroviral protease on eIF4GI
was more selective than that observed with poliovirus 2Apro.
Despite the presence of an intact endogenous eIF4GII, cleavage
of eIF4GI by HIV-1 PR was su⁄cient to impair drastically the
translation of capped and uncapped mRNAs. In contrast, polio-
virus IRES-driven translation was una¡ected or even enhanced
by HIV-1 PR after cleavage of eIF4GI. Further support for
these in vitro results has been provided by the expression of
HIV-1 PR in COS cells from a Gag-PR precursor. Our present
¢ndings suggest that eIF4GI intactness is necessary to maintain
cap-dependent translation, not only in cell-free systems but also
in mammalian cells.
< 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Translation in eukaryotes begins with the recruitment of
mRNAs by the 4F group of initiation factors (IF), which
recognize the cap structure present in mRNAs to promote
ribosome entry [1^3]. The eIF4F complex is composed of
three subunits: eIF4E, which binds to the cap structure of
mRNAs, the RNA helicase, eIF4A, which unwinds the even-
tual secondary structure present in mRNAs, and the eIF4G
subunit, which interacts with a number of proteins and initia-
tion factors, including PABP (poly(A)-binding protein), eIF3,
eIF4E and eIF4A [2,4,5]. Thus, the N-terminal half of eIF4G
contains the binding domains for eIF4E and PABP, whereas
the central part of eIF4G is responsible for the interaction
with eIF4A and eIF3 [6^11]. Finally, the C-terminal region
seems to be involved in regulating eIF4G activity [12,13]. A
novel form of eIF4G (eIF4GII) has been found that shares
V50% sequence homology with eIF4GI [14]. Data from in
vitro experiments suggested that eIF4GI and II factors could
be functionally exchangeable. Notably, translational shut-o¡
induced by poliovirus and rhinovirus appears to correlate with
cleavage of eIF4GII, rather than with the proteolysis of eIF4-
GI [15,16]. eIF4GII is less abundant in the cell than eIF4GI
and its exact contribution to the overall control of cell trans-
lation remains to be explored [16].
eIF4F has emerged as a key target in translational control
[2]. One of the best illustrated examples of this central role of
eIF4G comes from the proteolytic degradation of this factor
in cells subjected to conditions of stress, such as viral infec-
tions or apoptosis [1,17,18]. Caspase-mediated cleavage of
eIF4G precedes the inhibition of translation in cells under-
going apoptosis [19,20]. In addition, some members of the
picornavirus group encode viral proteases (enterovirus 2Apro
and aphthovirus Lpro) that cleave and inactivate eIF4GI lead-
ing to the shut-o¡ of host translation [21,22]. These proteases
also bisect eIF4GII, but with delayed kinetics [15,16]. Re-
cently, eIF4GI has also been described as a target for HIV-
1 protease (PR) [23,24]. While eIF4GI is cleaved once at po-
sitions 641 and 643 by 2Apro and Lpro, respectively, HIV-1 PR
cleaves at positions 678/681 and 1086 to separate this factor
into three moieties [24]. In all these instances, cleavage of
eIF4G by the viral protease uncouples the activity of the
factor domains, leading to the blockade of translation initia-
tion.
The impact of eIF4G cleavage on translation has been ex-
tensively analyzed, mainly using in vitro translation systems
programmed with synthetic mRNAs. Cleavage of eIF4G by
picornaviral proteases impairs translation of capped mRNAs,
whereas internal initiation of translation directed by IRES
elements is una¡ected or even enhanced by eIF4G cleavage
[25,26]. The e¡ect of eIF4G cleavage on translation of arti¢-
cially uncapped mRNAs is controversial. Some reports have
shown that translation of both capped and uncapped mRNAs
is inhibited to a similar extent, whereas other studies have
claimed that translation of uncapped mRNAs is not only re-
sistant, but is even increased upon cleavage of eIF4G [27^30].
In this report, we have analyzed the proteolytic activity of
HIV-1 PR on eIF4GI and eIF4GII and its e¡ect on trans-
lation of synthetic mRNAs in cell-free systems and in trans-
fected mammalian cells.
2. Materials and methods
2.1. Plasmid construction and in vitro synthesis of mRNAs
pKS-Luc and pT7 IRES Polio-Luc plasmids were described previ-
ously [31]. To construct pKS-5PLHIV-Luc plasmid, the entire 5P lead-
er region of HIV-1 (clone pNL4.3) was ampli¢ed by PCR using the
primers 5P (CGACGCGGCCGCGGTCTCTCTGGTTAGACC) and
3P (CGCAGACTAGTATCTCTCTCCTTCTAGCCTCC). The result-
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ing DNA fragment of 335 nucleotides was digested with NotI and
SpeI and cloned into pKS-Luc plasmid previously digested with the
same enzymes. pcDNA-GAG-PR was constructed by subcloning
the 5PLGAGPR fragment from pKS-5PLGAGPR plasmid into
pcDNA3.0 plasmid using NotI and StuI/SmaI enzymes [24]. In vitro
transcription was carried out with T7 RNA polymerase according to
the manufacturer’s instructions (Promega). For capping of mRNAs,
0.5 mM of CAP analogue (7mGTP, New England) was included in
the reactions and the concentration of GTP was reduced to 0.05 mM.
Transcription reactions were digested with DNase RQ1 and mRNAs
were puri¢ed through chroma-spin columns (Clontech) and analyzed
by agarose gel electrophoresis.
2.2. In vitro translations
Translation in HeLa cell extracts was carried out as described pre-
viously [32]. Brie£y, translation mixtures containing 70% (v/v) of
HeLa S10 extract were programmed with 10^100 ng of mRNA in a
¢nal volume of 12.5 Wl and incubated at 30‡C for 90 min. Luciferase
activity was measured in a Monolight luminometer. Translation in
rabbit reticulocyte lysates (RRL) (Promega) was performed according
to the manufacturer’s instructions, except that concentration of
KAcOH was optimized to 120 WM. 50 WCi of [35S]Met/Cys (Trans-
label, Amersham) was added and lysates were programmed with the
indicated amounts of mRNAs. The reaction was stopped by addition
of 2Usample bu¡er and analyzed by SDS^PAGE and autoradiogra-
phy.
2.3. Immunoblotting
50 Wg of total protein was analyzed by SDS^PAGE, transferred to
nitrocellulose membrane (Bio-Rad) and probed with the following
antibodies: anti-eIF4GI (1:1000 dilution), anti-eIF4GII (1:1000 dilu-
tion, a gift from N. Sonenberg) or anti-p24 (1:500 dilution, EV Pro-
Fig. 1. Kinetics of eIF4GI and eIF4GII cleavage by HIV-1 PR in HeLa cell extracts. A: Schematic diagram of eIF4GI depicting the domains
involved in the interaction with other initiation factors. The cleavage sites for HIV-1 PR and poliovirus 2Apro are also denoted, as well as the
main fragments of eIF4GI generated upon treatment with these proteases. The sequence alignments of cleavage sites of HIV-1 PR in eIF4GI
and eIF4GII are also indicated. B: HeLa S10 extracts (50 Wg) were incubated with 25 ng of HIV-1 PR or 2 Wg of MBP-2Apro for the indicated
time periods and analyzed by Western blot against eIF4GII. The membranes were then stripped and reprobed with anti-eIF4GI antibodies.
Cleavage products derived from eIF4GI and eIF4GII are indicated (arrowheads). C: Quanti¢cation of eIF4GI and eIF4GII cleavage from the
experiment shown in B. Bands corresponding to intact eIF4GI and eIF4GII were quanti¢ed by computer densitometry and expressed as a per-
centage of the control (no protease treatment).
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gramme EVA/MRC Centralised Facility for AIDS Reagents, NIBSC,
UK).
2.4. Transfection of mammalian cells
COS-7 cells (V0.3U105) were transfected with 1 Wg of pcDNA-
GAG-PR plasmid by coupled transfection/infection with recombinant
vT7-3, as described previously [31]. 16 h post treatment cells were
lysed in sample bu¡er and analyzed by Western blot. In cotransfection
experiments with pKS-Luc plasmid, cells were lysed in luciferase bu¡-
er (25 mM glycylglycine, pH 7.8, 1 mM dithiothreitol, 0.5% Triton
X-100) for luciferase activity measurements.
3. Results
3.1. Di¡erential cleavage of HIV-1 PR on eIF4GI and eIF4GII
in vitro
To assay the proteolytic activity of HIV-1 PR on eIF4GI
and eIF4GII, HeLa S10 extracts were incubated with puri¢ed
HIV-1 PR and the integrity of eIF4G factors was analyzed at
di¡erent times. For comparison, cell extracts were also incu-
bated with poliovirus 2Apro. As shown in Fig. 1B, both polio-
virus 2Apro and HIV-1 PR e⁄ciently cleaved eIF4GI giving
rise to the previously characterized band pattern of proteolytic
products [24]. However, the kinetics of eIF4GI hydrolysis by
these two proteases di¡ered. HIV-1 PR hydrolyzed eIF4GI
more rapidly than poliovirus 2Apro. Thus, an almost complete
cleavage of eIF4GI was achieved for HIV-1 PR after 30 min
of incubation, whereas 70% of the initiation factor remained
intact at this time when incubated with poliovirus 2Apro (Fig.
1C). More extensive proteolysis of eIF4GI by poliovirus 2Apro
required longer incubation times (90 min), although it did not
yield the thorough degradation observed with HIV-1 PR.
Next, the kinetics of eIF4GII proteolysis by these two viral
proteases were examined. Cleavage of eIF4GII by poliovirus
2Apro was slightly delayed in comparison with eIF4GI (Fig.
1C). This result agrees closely with previous reports showing
some preferential activity of picornaviral 2Apro on eIF4GI
[15]. Notably, no gross modi¢cation of eIF4GII was observed
after incubation of HeLa extracts with HIV-1 PR. Densito-
metric quanti¢cation revealed neither a signi¢cant reduction
of intact eIF4GII nor the appearance of smaller products
related to this factor.
3.2. E¡ects of HIV-1 PR on translation of capped, uncapped
and poliovirus IRES-containing mRNAs
Given the preferential activity of HIV-1 PR on eIF4GI, we
focussed our interest on the impact of HIV-1 PR on trans-
lation in the presence of intact eIF4GII. To this end, several
mRNAs bearing di¡erent 5P non-coding sequences were syn-
thesized (Fig. 2A). HeLa cell extracts were preincubated with
the indicated amounts of HIV-1 PR or poliovirus 2Apro. The
integrity of eIF4GI and eIF4GII was analyzed before addition
Fig. 2. E¡ect of HIV-1 PR-mediated cleavage of eIF4GI on translation in HeLa cell extracts. A: Diagram of synthetic mRNAs used to pro-
gram the in vitro translations. B: HeLa cell extracts were preincubated with 25 ng HIV-1 PR (with or without 1.5 WM saquinavir (SQ)) or 2 Wg
MBP-2Apro for 30 min and 2 h, respectively. Afterwards, 1.5 WM of saquinavir was added to all samples to neutralize the activity of HIV-1
PR and an aliquot was taken to analyze the integrity of eIF4G factors before the addition of mRNAs. C: Luciferase activities were measured
after programming extracts with 200 ng of cap-Luc, 200 ng of uncapped Luc or 10 ng of IRES Polio-Luc mRNAs and incubation at 30‡C for
90 min. Since poliovirus IRES-driven translation was much more e⁄cient than cap-dependent translation in these extracts, values of luciferase
activity obtained for IRES Polio-Luc mRNAs were divided by 5. RLU: relative light units. D: Means of three independent experiments, ex-
pressed as percentage inhibition with respect to control samples. E: E¡ect of MBP-2Apro treatment on translation of the indicated mRNAs.
Data were calculated as described in D.
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of di¡erent mRNAs. Cleavage of eIF4GI by HIV-1 PR was
almost complete, whereas 20% of eIF4GI remained intact
upon treatment with poliovirus 2Apro (Fig. 2B). In addition,
poliovirus 2Apro also degraded eIF4GII by 50%. No reduction
of the intact form of eIF4GII was observed upon incubation
with HIV-1 PR. However, it should be noted that treatment
with HIV-1 PR induced the disappearance of the lowest mo-
bility band of eIF4GII.
Preincubation of extracts with HIV-1 PR largely prevented
the translation of capped and uncapped luciferase mRNAs
(90% inhibition), but no decrease of luciferase synthesis was
found with the mRNA bearing the poliovirus IRES sequence
(Fig. 2C,D). Notably, HIV-1 PR-mediated inhibition of trans-
lation was even stronger (98%) in the case of luciferase
mRNAs bearing the 5P leader of HIV-1. It should be noted
that when 5P leader of HIV-1 was placed before the luciferase
coding region, translation of this mRNA was three- to ¢ve-
fold inhibited compared with capped mRNA (Fig. 2D). In
contrast, translation of luciferase mRNAs driven by poliovi-
rus IRES was resistant to cleavage of eIF4GI. Similar results
were obtained for poliovirus 2Apro, although the extent of
translational inhibition obtained was lower than with HIV-1
PR (Fig. 2E).
In addition, the e¡ect of HIV-1 PR was tested on the trans-
lation of synthetic mRNAs in RRL. As shown in Fig. 3A,
intact eIF4GI was reduced by 70% upon incubation with
HIV-1 PR, although the resulting cleavage fragments of eIF4-
GI were not detected. Our antibodies raised against human
eIF4GI also failed to detect HIV-1 PR-induced cleavage prod-
ucts of rabbit eIF4GI, as described previously [29]. In con-
trast, no cleavage of eIF4GII by HIV-1 PR was apparent in
RRL (Fig. 3A) even at the highest concentration of protease
tested (data not shown). Nevertheless, translation of capped
luciferase mRNAs was inhibited by 60% upon HIV-1 PR
treatment, which correlates with the extent of eIF4GI cleavage
(Fig. 3A). As was the case with HeLa cell extracts, translation
driven by IRES of EMC virus was slightly stimulated by
HIV-1 PR treatment (Fig. 3B).
3.3. E¡ect of HIV-1 PR on translation in mammalian cells
To analyze the activity of HIV-1 PR on translation in intact
cells, COS-7 cells were transfected with a plasmid encoding
the entire Gag precursor of HIV-1 followed by the PR gene.
HIV-1 PR was active in transfected cells as evidenced by the
processing of the Gag precursor to yield CA, MA and CA^
MA proteins, as occurs in HIV-1-infected cells (Fig. 4A). The
action of HIV-1 PR and the subsequent processing of Gag
precursor were completely prevented by addition of 2 WM
saquinavir to the cell culture. Notably, expression of Gag-
PR in transfected cells induced the cleavage of eIF4GI. In
addition, a slight modi¢cation in the mobility of the eIF4GII
band was observed, but no cleavage products derived from
this factor could be detected.
We next analyzed the e¡ect of HIV-1 PR on the expression
of luciferase gene from a pKS-Luc plasmid. Cotransfection of
pcDNA-Gag-PR with pKS-Luc inhibited luciferase synthesis
by 70%. Notably, this inhibition was prevented when saqui-
navir was added to the cell cultures (Fig. 4B). This ¢nding
indicates that HIV-1 PR is responsible for the inhibitory e¡ect
on luciferase synthesis. Consistent with our in vitro results,
the synthesis of poliovirus 2C protein driven by EMC virus
IRES was not a¡ected by Gag-PR expression (Fig. 4C).
4. Discussion
Our initial ¢nding that HIV-1 PR had the capacity to pro-
teolyse the initiation factor of translation eIF4G provided new
clues for the investigation of the regulation of translation in
retroviruses [24]. Now we demonstrate that HIV-1 PR selec-
tively proteolyses eIF4GI very e⁄ciently in cell-free systems.
In contrast, eIF4GII seems not to su¡er any major degrada-
tion, since no cleavage products were identi¢ed under our
experimental conditions. However, there is evidence that the
electrophoretic mobility of eIF4GII changes slightly. eIF4GII
usually runs in polyacrylamide gels as a close doublet; after
HIV-1 PR incubation, the upper form disappears, while the
amount of the lower form increases. A partial di¡erential
sensitivity of eIF4GI and eIF4GII to cleavage by picornaviral
proteases has been reported before [15,16]. We now document
that the preferential proteolysis of the eIF4GI form over the
degradation of eIF4GII is exacerbated in the case of HIV-1
PR. Notably, some ¢ndings presented here agree with recently
published data [23]. Several explanations can be put forward
to account for the preferential cleavage of the eIF4GI form by
HIV-1 PR. The distal and proximal cleavage sites for HIV-1
PR surrounding position 680 in the eIF4GI sequence are
poorly conserved in eIF4GII. Thus, the Ala678 at the N-ter-
Fig. 3. E¡ect of HIV-1 PR on translation in RRL. Lysates were
treated or not with 25 ng of HIV-1 PR for 30 min, followed by the
addition of 1.5 WM of saquinavir. An aliquot of lysates was ana-
lyzed by Western blot against eIF4GI and eIF4GII (A) and the re-
maining lysate was used to program translations with 10 ng of
EMC-2C or 50 ng of cap-Luc mRNAs (B). Quanti¢cation of bands
was carried out by computer densitometry and data are expressed
as percentage of control with respect to untreated lysates.
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minus of the distal hydrolyzable peptide bond is absent in
eIF4GII (Fig. 1A). In addition, the proximal dipeptide
L-M681 in eIF4GI that is also cleaved by HIV-1 PR has no
counterpart in eIF4GII, where a dipeptide S-V is present in-
stead. In fact, the £anking sequences present at the cleavage
sites are conserved in both eIF4GI and eIF4GII. Therefore,
the di¡erences in primary sequence probably make eIF4GII
refractory to cleavage by HIV-1 PR at positions 678/681. Less
clear is the lack of HIV-1 PR cleavage at position 1086 of
eIF4GII, since this site and the £anking sequences are con-
served in both factors. Therefore, in this case the lack of
cleavage of the eIF4GII form may be ascribed to conforma-
tional constraints that make this site inaccessible to HIV-1
PR. The di¡erential activity of HIV-1 PR on eIF4GI has
provided a system with which to test the speci¢c role that
this form of eIF4G plays in translation in cell-free systems
and in transfected cells. Our data indicate that in vitro trans-
lation of capped and uncapped luciferase mRNAs is strictly
dependent on eIF4GI integrity. Translation was almost com-
pletely inhibited in HeLa cell extracts when eIF4GI was pro-
teolysed by HIV-1 PR even though eIF4GII remained unde-
graded. This dependence of protein synthesis on eIF4GI was
even higher when a luciferase mRNA bearing the 5P leader
region of HIV-1 was used to program cell-free systems. This
result agrees with the notion that translation of mRNAs bear-
ing highly structured regions, like that present in the 5P leader
of HIV-1 genome, were more dependent on eIF4F activity
[33,34]. However, translation driven by picornaviral IRES
was not a¡ected by eIF4GI cleavage, thus agreeing well
with previous ¢ndings [25,26].
The di¡erential activity of HIV-1 PR on the two forms of
eIF4G was also observed in RRL, although cleavage of eIF4-
GI by HIV-1 PR was less e⁄cient than in HeLa cell extracts.
This observation correlates with the lower inhibition of lucif-
erase translation in RRL. Thus, there is a close parallel be-
tween the intactness of eIF4GI and the extent of cap-depen-
dent translation. These results agree with recently published
data from Ohlman et al. [23] showing a poor inhibition (30^
40%) of cap-dependent translation in RRL upon HIV-1 PR
treatment. Surprisingly, FMDV IRES-driven translation was
also weakly compromised (20^30% inhibition) in HIV-1 PR-
treated RRL extracts. In our opinion, RRL do not represent a
good system to analyze the HIV-1 PR-mediated cleavage of
eIF4G on translation.
Taken together, our results illustrate that eIF4GI supports
most of the initiation events in cell-free translation systems.
These data were also corroborated in transfected cells, and are
consistent with the fact that eIF4GI is more abundant in the
cell than eIF4GII [16]. However, our results partially contrast
with those reported by Gradi et al. [14]. These authors sug-
gested that eIF4GI and eIF4GII were functionally inter-
changeable, based on the observation that addition of re-
combinant eIF4GII restored translation in extracts depleted
of eIF4GI in cell extracts. However, the role that eIF4GII
plays in the control of translation in intact cells has not yet
been elucidated, perhaps because picornaviral proteases dis-
criminate poorly between eIF4GI and eIF4GII cleavage. The
¢nding that HIV-1 PR speci¢cally targets eIF4GI raises the
possibility of dissecting the separate roles that eIF4GI and
eIF4GII play in translation.
Fig. 4. E¡ect of HIV-1 Gag-PR expression on translation in transfected cells. COS cells were cotransfected with 0.5 Wg of pcDNA-GAG-PR
and 0.15 Wg of pKS-Luc plasmids as described in Section 2. Where indicated, cell cultures were treated with 2 WM saquinavir (SQ) and extracts
were obtained at 16 h post treatment. A: An aliquot was analyzed by Western blot against HIV-1 p24 (left), eIF4GI (middle) and eIF4GII
(right). B: Luciferase activity of extracts. C: Western blot against poliovirus 2C protein.
FEBS 26849 19-12-02
C. Perales et al./FEBS Letters 533 (2003) 89^94 93
Acknowledgements: We thank N. Sonenberg and E. Wimmer for pro-
viding us with anti-eIF4GII serum and HeLa S10 extracts, respec-
tively. We also thank S. Masciotra for a critical reading of the manu-
script. C.P. is a fellow of the Fondo de Investigaciones Sanitarias
(FIS), Spain. Projects DGICYT PM99-002 and FIS are acknowl-
edged for ¢nancial support. The Centro de Biolog|¤a Molecular was
in receipt of an institutional grant from the Fundacio¤n Ramo¤n Are-
ces, Spain.
References
[1] Gale Jr., M., Tan, S.L. and Katze, M.G. (2000) Microbiol. Mol.
Biol. Rev. 64, 239^280.
[2] Gingras, A.C., Raught, B. and Sonenberg, N. (1999) Annu. Rev.
Biochem. 68, 913^963.
[3] Pain, V.M. (1996) Eur. J. Biochem. 236, 747^771.
[4] Morley, S.J., Curtis, P.S. and Pain, V.M. (1997) RNA 3, 1085^
1104.
[5] Pestova, T.V., Kolupaeva, V.G., Lomakin, I.B., Pilipenko, E.V.,
Shatsky, I.N., Agol, V.I. and Hellen, C.U. (2001) Proc. Natl.
Acad. Sci. USA 98, 7029^7036.
[6] Imataka, H., Gradi, A. and Sonenberg, N. (1998) EMBO J. 17,
7480^7489.
[7] Korneeva, N.L., Lamphear, B.J., Hennigan, F.L. and Rhoads,
R.E. (2000) J. Biol. Chem. 275, 41369^41376.
[8] Lamphear, B.J., Kirchweger, R., Skern, T. and Rhoads, R.E.
(1995) J. Biol. Chem. 270, 21975^21983.
[9] Mader, S., Lee, H., Pause, A. and Sonenberg, N. (1995) Mol.
Cell. Biol. 15, 4990^4997.
[10] Marcotrigiano, J., Lomakin, I.B., Sonenberg, N., Pestova, T.V.,
Hellen, C.V. and Burkey, S.K. (2001) Mol. Cell 7, 193^203.
[11] Ali, I.K., Mckendrick, L., Morley, S.J. and Jackson, R.J. (2001)
EMBO J. 20, 4233^4242.
[12] Morino, S., Imataka, H., Svitkin, Y.V., Pestova, T.V. and Sonen-
berg, N. (2000) Mol. Cell. Biol. 20, 468^477.
[13] Pyronnet, S., Imataka, H., Gingras, A.C., Fukunaga, R., Hunter,
T. and Sonenberg, N. (1999) EMBO J. 18, 270^279.
[14] Gradi, A., Imataka, H., Svitkin, Y.V., Rom, E., Raught, B.,
Morino, S. and Sonenberg, N. (1998) Mol. Cell. Biol. 18, 334^
342.
[15] Gradi, A., Svitkin, Y.V., Imataka, H. and Sonenberg, N. (1998)
Proc. Natl. Acad. Sci. USA 95, 11089^11094.
[16] Svitkin, Y.V., Gradi, A., Imataka, H., Morino, S. and Sonen-
berg, N. (1999) J. Virol. 73, 3467^3472.
[17] Clemens, M.J., Bushell, M., Je¡rey, I.W., Pain, V.M. and Mor-
ley, S.J. (2000) Cell Death Di¡er. 7, 603^615.
[18] Thompson, S.R. and Sarnow, P. (2000) Curr. Opin. Microbiol. 3,
366^370.
[19] Bushell, M., McKendrick, L., Janicke, R.U., Clemens, M.J. and
Morley, S.J. (1999) FEBS Lett. 451, 332^336.
[20] Marissen, W.E. and Lloyd, R.E. (1998) Mol. Cell. Biol. 18, 7565^
7574.
[21] Etchison, D., Milburn, S.C., Edery, I., Sonenberg, N. and Her-
shey, J.W. (1982) J. Biol. Chem. 257, 14806^14810.
[22] Kirchweger, R., Ziegler, E., Lamphear, B.J., Waters, D., Liebig,
H.D., Sommergruber, W., Sobrino, F., Hohenadl, C., Blaas, D.
and Rhoads, R.E. et al. (1994) J. Virol. 68, 5677^5684.
[23] Ohlmann, T., Prevot, D., Decimo, D., Roux, F., Garin, J., Mor-
ley, S.J. and Darlix, J.L. (2002) J. Mol. Biol. 318, 9^20.
[24] Ventoso, I., Blanco, R., Perales, C. and Carrasco, L. (2001) Proc.
Natl. Acad. Sci. USA 98, 12966^12971.
[25] Ohlmann, T., Rau, M., Pain, V.M. and Morley, S.J. (1996)
EMBO J. 15, 1371^1382.
[26] Pestova, T.V., Shatsky, I.N. and Hellen, C.U. (1996) Mol. Cell.
Biol. 16, 6870^6878.
[27] Borman, A.M., Kirchweger, R., Ziegler, E., Rhoads, R.E., Skern,
T. and Kean, K.M. (1997) RNA 3, 186^196.
[28] De Gregorio, E., Preiss, T. and Hentze, M.W. (1998) RNA 4,
828^836.
[29] Novoa, I., Martinez-Abarca, F., Fortes, P., Ortin, J. and Car-
rasco, L. (1997) Biochemistry 36, 7802^7809.
[30] Ohlmann, T., Rau, M., Morley, S.J. and Pain, V.M. (1995) Nu-
cleic Acids Res. 23, 334^340.
[31] Ventoso, I., Barco, A. and Carrasco, L. (1998) J. Biol. Chem.
273, 27960^27967.
[32] Molla, A., Paul, A.V. and Wimmer, E. (1991) Science 254, 1647^
1651.
[33] Koromilas, A.E., Lazaris-Karatzas, A. and Sonenberg, N. (1992)
EMBO J. 11, 4153^4158.
[34] Parkin, N.T., Cohen, E.A., Darveau, A., Rosen, C., Haseltine,
W. and Sonenberg, N. (1988) EMBO J. 9, 2831^2837.
FEBS 26849 19-12-02
C. Perales et al./FEBS Letters 533 (2003) 89^9494
